Daniel Yim

Daniel Yim

Auto-generated profile, based on publicly available information

Daniel Yim

Antimicrobial Resistance IRG, Singapore-MIT Alliance for Research and Technology, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2016 in Nature Chemical Biology
Verified
Journal Article
Closed access
KLKaiwen Ivy Liu
Kaiwen Ivy Liu
MRMuhammad Nadzim Bin Ramli
Muhammad Nadzim Bin Ramli
CWCheok Wei Ariel Woo
Cheok Wei Ariel Woo
YWYuanming Wang
Yuanming Wang
TZTianyun Zhao
Tianyun Zhao
MTMeng How Tan
Meng How Tan

12 June 2019 in EMBO Reports
Verified
Journal Article
Open access
PDF file
SKSrikar Krishna
Srikar Krishna
DYDaniel Gr Yim
Daniel Gr Yim
VLVairavan Lakshmanan
Vairavan Lakshmanan
VTVarsha Tirumalai
Varsha Tirumalai
JKJudice Ly Koh
Judice Ly Koh
Ramanuj DasGuptaRamanuj DasGupta
Ramanuj DasGupta
Transfer RNA (tRNA)‐derived small RNAs (tsRNAs) have recently emerged as important regulators of protein translation and shown to have diverse biological functions. However, the underlying cellular and molecular mechanisms of tsRNA function in the context of dynamic cell‐state transitions remain unclear. Expression analysis of tsRNAs in distinct heterologous cell and tissue models of stem vs. differentiated states revealed a differentiation‐dependent enrichment of 5′‐tsRNAs. We report the identification of a set of 5′‐tsRNAs that is upregulated in differentiating mouse embryonic stem cells (mESCs). Notably, interactome studies with differentially enriched 5′‐tsRNAs revealed a switch in their association with “effector” RNPs and “target” mRNAs in different cell states. We demonstrate that specific 5′‐tsRNAs can preferentially interact with the RNA‐binding protein, Igf2bp1, in the RA‐induced differentiated state. This association influences the transcript stability and thereby translation of the pluripotency‐promoting factor, c‐Myc, thus providing a mechanistic basis for how 5′‐tsRNAs can modulate stem cell states in mESCs. Together our study highlights the role of 5′‐tsRNAs in defining distinct cell states.

15 April 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JHJennifer F. Hu
Jennifer F. Hu
DYDaniel Yim
Daniel Yim
DMDuanduan Ma
Duanduan Ma
SHSabrina M. Huber
Sabrina M. Huber
NDNick Davis
Nick Davis
BCBo Cao
Bo Cao

17 January 2012 in The EMBO Journal
Verified
Journal Article
Closed access
MMManjeet Mukherjee
Manjeet Mukherjee
SCSoah Yee Chow
Soah Yee Chow
PYPermeen Yusoff
Permeen Yusoff
JSJ Seetharaman
J Seetharaman
CNCherlyn Ng
Cherlyn Ng
JSJayaraman Sivaraman
Jayaraman Sivaraman

22 January 2014 in Oncogene
Verified
Journal Article
Open access
PDF file
DYD G R Yim
D G R Yim
SUJOY GHOSHSUJOY GHOSH
SUJOY GHOSH
GGG R Guy
G R Guy
DVD M Virshup
D M Virshup
Sprouty2 (SPRY2) is a potent negative regulator of receptor tyrosine kinase signaling, and is implicated as a tumor suppressor. SPRY2 inhibits FGF–RAS–ERK signaling by binding to growth factor receptor bound protein 2 (GRB2) during fibroblast growth factor receptor (FGFR) activation, disrupting the GRB2–SOS (son of sevenless) complex that transduces signals from FGFR to RAS. SPRY2 binding to GRB2 is modulated by phosphorylation but the key regulatory kinase(s) are not known. Prior studies identified the frequent presence of CK1 phosphorylation motifs on SPRY2. We therefore tested if CK1 has a role in SPRY2 phosphorylation and function. Loss of CK1 binding and inhibition of CK1 activity by two structurally distinct small molecules abrogated SPRY2 inhibition of FGF–ERK signaling, leading to decreased SPRY2 interaction with GRB2. Moreover, CK1 activity and binding are necessary for SPRY2 inhibition of FGF-stimulated neurite outgrowth in PC12 cells. Consistent with its proposed role as an inhibitor of FGF signaling, we find that CSNK1E transcript abundance negatively correlates with FGF1/FGF7 message in human gastric cancer samples. Modulation of CK1 activity may be therapeutically useful in the treatment of FGF/SPRY2-related diseases.

1 June 2021 in iScience
Verified
Journal Article
Open access
JLJoo-Leng Low
Joo-Leng Low
WDWeina Du
Weina Du
TGTenzin Gocha
Tenzin Gocha
GOGokce Oguz
Gokce Oguz
XZXiaoqian Zhang
Xiaoqian Zhang
Ramanuj DasGuptaRamanuj DasGupta
Ramanuj DasGupta
Here we report a molecular docking-based approach to identify small molecules that can target the β-catenin (β-cat)-TCF4 protein-protein interaction (PPI), a key effector complex for nuclear Wnt signaling activity. Specifically, we developed and optimized a computational model of β-cat using publicly available β-cat protein crystal structures, and existing β-cat-TCF4 interaction inhibitors as the training set. Using our computational model to an in silico screen predicted 27 compounds as good binders to β-cat, of which 3 were identified to be effective against a Wnt-responsive luciferase reporter. In vitro functional validation experiments revealed GB1874 as an inhibitor of the Wnt pathway that targets the β-cat-TCF4 PPI. GB1874 also affected the proliferation and stemness of Wnt-addicted colorectal cancer (CRC) cells in vitro. Encouragingly, GB1874 inhibited the growth of CRC tumor xenografts in vivo, thus demonstrating its potential for further development into therapeutics against Wnt-associated cancer indications.